Literature DB >> 9426068

Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.

E Santoni-Rugiu1, M R Jensen, S S Thorgeirsson.   

Abstract

The oncogene c-myc and transforming growth factor (TGF) alpha are frequently coexpressed in human cancers, suggesting that their interaction may be a critical step in malignant growth. Consistent with this idea, we recently demonstrated in a transgenic mouse model that TGF-alpha dramatically enhances c-myc-induced hepatocarcinogenesis. To elucidate this synergistic effect, we have now investigated regulation of cell cycle and apoptosis during neoplastic development in the liver of c-myc and c-myc/TGFalpha transgenic mice. Both lines displayed dramatic increases of mitotic and apoptotic rates before the onset of hepatocellular carcinoma (HCC), but only c-myc/TGF-alpha livers showed significant levels of net proliferation (mitosis minus apoptosis). Subsequently, mitosis declined in peritumorous tissues, concomitant with the previously reported induction of TGF-beta1, whereas c-myc and c-myc/TGFalpha HCCs maintained mitotic hyperactivity. The c-myc/TGF-alpha HCCs were also characterized by a particularly strong expression of TGF-alpha and very low apoptotic index in contrast to high levels of apoptosis in peritumorous tissues and c-myc HCCs. The differential levels of cell proliferation in noncancerous and cancerous tissues correlated with a stronger induction of cyclin D1 mRNA and protein in c-myc/TGF-alpha and c-myc HCCs associated with intense pRb hyperphosphorylation. Severe deregulation of G1-S transition was also indicated by the dramatic up-regulation, particularly in the HCCs, of pRb-free E2F1-DP1 and E2F2-DP1 transcription factor heterodimers, as assessed by immunoprecipitation and immunohistochemistry. The existence of increased E2F activity during hepatocarcinogenesis was further indicated by the transcriptional induction of putative E2F target genes involved in cell cycle progression, such as endogenous c-myc, cyclin A, Cdc2, and E2F itself. Cdc2 overexpression and the elevated mitotic indices in the HCCs correlated also with induction of cyclin B steady-state levels. The data suggest that coexpression of c-myc and TGF-alpha leads to a selective growth advantage for hepatic (pre)neoplastic cells by disrupting the pRb/E2F pathway and by TGF-alpha-mediated reduction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9426068

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway.

Authors:  E Santoni-Rugiu; J Falck; N Mailand; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 2.  Moving toward an understanding of the metastatic process in hepatocellular carcinoma.

Authors:  W M Korn
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

3.  Over-expression of cyclin D1 regulates Cdk4 protein synthesis.

Authors:  M A Parker; N G Deane; E A Thompson; R H Whitehead; S K Mithani; M K Washington; P K Datta; D A Dixon; R D Beauchamp
Journal:  Cell Prolif       Date:  2003-12       Impact factor: 6.831

4.  Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

Authors:  Gong Yang; Bin Chang; Fan Yang; Xiaoqing Guo; Kathy Qi Cai; Xue Sherry Xiao; Huamin Wang; Subrata Sen; Mien-Chie Hung; Gordon B Mills; Sandy Chang; Asha S Multani; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

5.  Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway.

Authors:  Xiao-Ming Ou; Kevin Chen; Jean C Shih
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-07       Impact factor: 11.205

6.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma.

Authors:  Julia Freimuth; Nikolaus Gassler; Nives Moro; Rolf W Günther; Christian Trautwein; Christian Liedtke; Gabriele A Krombach
Journal:  Mol Cancer       Date:  2010-04-29       Impact factor: 27.401

Review 8.  Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

9.  Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease.

Authors:  Drazen B Zimonjic; Veronika Ullmannova-Benson; Valentina M Factor; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Cancer Genet Cytogenet       Date:  2009-05

10.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.